




RealRate

# PHARMACEUTICAL 2019

Imunon Inc.  
Rank 207 of 363





RealRate

# PHARMACEUTICAL 2019

Imunon Inc.  
Rank 207 of 363



The relative strengths and weaknesses of Imunon Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Imunon Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Imunon Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 29% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	28,131
Cost of Goods Sold	0
Intangible Assets	2,544
Liabilities, Current	6,107
Liabilities, Non-Current	63
Other Assets	15,995
Other Compr. Net Income	40
Other Expenses	-10,419
Other Liabilities	19,825
Other Net Income	-1,237
Other Revenues	500
Property and Equipment	185
Research and Development	11,866
Selling, General and Administrative Expense	9,700

Output Variable	Value in 1000 USD
Assets	46,856
Liabilities	25,995
Expenses	11,146
Revenues	500
Stockholders Equity	20,861
Net Income	-11,883
Comprehensive Net Income	-11,863
Economic Capital Ratio	66%